A Phase 2 interventional study of Bisoprolol; Perindopril; in Women With Breast Cancer, sponsored by State Institution "Republican Scientific and Practical Center" Cardiology, Belarus. Completed at 1 site in Belarus. Open to female participants. Per ClinicalTrials.gov, last updated 2023-02-08.
Sponsored by State Institution "Republican Scientific and Practical Center" Cardiology, Belarus · Phase 2, Interventional, and Prevention
To develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular complications
Purpose of the study: to develop a method of medical prevention of cardiovascular diseases caused by cardiotoxicity against the background of complex treatment of patients with primary resectable breast cancer to reduce the risk of cardiovascular complications
Exclusion Criteria:
women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, untreated
women with breast cancer, with a morphologically confirmed diagnosis before the appointment of anticancer therapy, receiving treatment with a combination of bisoprolol and perindopril
Drug: Bisoprolol; Perindopril;
based on the results of the patient study, different drug therapy regimens for cardiovascular complications during chemotherapy will be proposed
Also known as: Bisoprolol; Perindopril
development of cardiovascular diseases and complications
hypertension, cardiomyopathy, arrhythmia's, myocardial infarction, heart failure
Time frame: 4 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
State Institution "Republican Scientific and Practical Center" Cardiology, Belarus